UNSPSC 51123111: Ibutilide fumarate

This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula 2C20H36N2O3S.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9L5X4M5L6I. European Medicines Agency schedules ibutilide fumarate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14176MIG. Most nations, for tariff and trade purposes, schedule ibutilide fumarate under HS 29350090 and SITC 51580. As of Q4 2014, IBUTILIDE FUMARATE remains US FDA's Preferred Term for this commodity.

Ibutilide fumarate bears US NLM identifiers UMLS ID C0644117 and NCI Concept Code C47561. SMILES: CCCCCCCN(CC)CCCC(C1CCC(CC1)NS(=O)(=O)C)O.CCCCCCCN(CC)CCCC(C1CCC(CC1)NS(=O)(=O)C)O.C(=C/C(=O)O)\C(=O)O.

UNSPSC 51123111 Ibutilide fumarate, a Commodity code, describes a specific cardiac antiarrhythmic injection used in emergency and acute-care settings. State and local governments procure this medication primarily through emergency medical services departments, public health agencies, and cooperative purchasing vehicles that aggregate pharmaceutical demand across multiple jurisdictions. The work involves direct supply of the drug product to authorized wholesalers or end-use facilities, with vendors responsible for meeting FDA manufacturing standards, expiration-date requirements, and regulatory compliance under the Drug Supply Chain Security Act. Issuing bodies range from municipal fire-rescue departments managing Advanced Life Support medication stocks to state health agencies and multistate cooperative purchasing alliances sourcing generic pharmaceuticals for distributed delivery networks.

Recent activity appears concentrated in emergency-services procurement and state-level cooperative purchasing. The City of Tampa's Purchasing Department issued an IFB in April 2026 (Solicitation 26P00188) for Advanced Life Support Medications including related agents for Tampa Fire Rescue, with a $40,000 estimated contract value and a Small Local Business Enterprise sheltered-market designation offering a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted an RFP in January 2026 (Solicitation S1070000015802) for generic multi-source pharmaceuticals and OTC products with distribution across participating state and local government facilities in Minnesota and Oregon, requiring vendors to work through three authorized wholesalers and meet cGMP and DSCSA compliance standards with response due March 26, 2026. The Texas Health and Human Services Commission issued an RFI in April 2026 to explore direct-to-manufacturer pharmacy programs, signaling emerging state interest in alternative pharmaceutical supply models.